Clinical trials: Castration-Resistant Prostatic Cancer
Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
This phase II/II trial compares the effect of high dose testosterone followed by darolutamide with the usual care in treating patients with prostate cancer that has spread from where it first started (primary site) to other…
- Trial name
- NCT07852195
- Testing
- Abiraterone Acetate, Biospecimen Collection, Bone Scan
- Volunteers
- 432 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Metastatic Castration-Resistant Prostate Cancer, mCRPC
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants
This study will test an experimental Regeneron drug called REGN21353 ("study drug") to see if it can help treat previously treated prostate cancer that has spread (also called metastatic castration-resistant prostate cancer or…
- Trial name
- NCT07850921
- Testing
- REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency)
- Volunteers
- 192 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer, Castration-resistant Prostate Cancer
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer
Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone may be required for clinical response.
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT05081193
- Testing
- Testosterone Undecanoate, Enzalutamide
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms, Castration-Resistant
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative…
- Trial name
- QUEST (NCT03431350)
- Testing
- Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg
- Where
- 50 sites in United States, Belgium and 5 more
- Volunteers
- 136 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a…
- Trial name
- NCT02123758
- Testing
- Abiraterone Acetate, Prednisone, JNJ-56021927
- Where
- 7 sites in United States, Canada and 2 more
- Volunteers
- 57 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostatic Neoplasms, Castration-Resistant
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the effects of repeat dosing of JNJ-56021927 on the pharmacokinetics for single-dose multiple cytochrome P450 (CYP450) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2C8) and transporter (P-gp and…
- Trial name
- NCT02592317
- Testing
- JNJ 56021927, Drug Cocktail, Pioglitazone
- Where
- 3 sites in Moldova, Spain
- Volunteers
- 23 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Castration-Resistant Prostatic Cancer
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
- Trial name
- MAGNITUDE (NCT03748641)
- Testing
- Niraparib, Abiraterone Acetate, Prednisone
- Where
- 318 sites in United States, Argentina and 27 more
- Volunteers
- 765 people
- Sponsor
- Janssen Research & Development, LLC
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
The purpose of this study is to collect long-term safety data in participants with cancers including acute myeloid leukemia, non-Hodgkin lymphoma, myelodysplastic syndrome, chronic lymphocytic leukemia (type of cancer of the…
- Conditions
- Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT06788509
- Testing
- JNJ-75348780, JNJ-67856633, JNJ-54179060
- Where
- 39 sites in Australia, Belgium and 13 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT06801236
- Testing
- ACE-232 tablets
- Where
- 13 sites in United States, China
- Volunteers
- 88 people
- Sponsor
- Acerand Therapeutics (Hong Kong) Limited
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 174 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostatic Neoplasms, Castration-Resistant
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by…
- Trial name
- KLK2-PASenger (NCT07225946)
- Testing
- Pasritamig, Docetaxel, Prednisone/Prednisolone
- Where
- 158 sites in United States, Australia and 15 more
- Volunteers
- 800 people
- Sponsor
- Janssen Research & Development, LLC
Metastatic Castration Resistant Prostate Cancer, mCRPC
A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms
- Trial name
- NCT07719361
- Testing
- FX-111
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Flare Therapeutics Inc.
Metastatic Castration Resistant Prostate Cancer
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency…
- Trial name
- CHOMP (NCT04104893)
- Testing
- Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Metastatic Castration Resistant Prostate Cancer
A Phase 1 Study of Autologous Dendritic Cell Immunotherapy in Patients With mCRPC
The goal of this clinical trial was to evaluate the safety of Cellgram-DC-PC, an autologous dendritic cell-based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04615845
- Testing
- Cellgram-DC-PC
- Where
- South Korea
- Volunteers
- 3 people
- Sponsor
- Pharmicell Co., Ltd.
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
This clinical trial will evaluate the safety and efficacy of [161Tb]Tb -PSMA-I\&T in men with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- VIOLET (NCT05521412)
- Testing
- [ 161 Tb]Tb PSMA I&T
- Where
- Australia
- Volunteers
- 66 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abiraterone.
- Trial name
- NCT05011188
- Testing
- FOR46, Enzalutamide, Pegfilgrastim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Rahul Aggarwal
Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC)
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults…
- Conditions
- Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Metastatic Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer Patients
- Trial name
- PSMA-013-001 (NCT07813637)
- Testing
- JANX013, JANX007
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Janux Therapeutics
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Cannabidiol for Pain Relief of Patients With End-stage mCRPC
The goal of this clinical trial is to evaluate the effects of cannabidiol in patients with end-stage metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- ProCan (NCT07549256)
- Testing
- Cannabidiol
- Where
- Denmark
- Volunteers
- 58 people
- Sponsor
- Regionshospital Nordjylland
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT02522715
- Testing
- Cabazitaxel, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute